EFFEXOR XR (venlafaxine hydrochloride) by Viatris (2) is mdd, gad, sad, and pd is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake. First approved in 1997.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
EFFEXOR XR is an extended-release oral capsule formulation of venlafaxine hydrochloride approved in 1997 for treatment of major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder (SAD), and panic disorder (PD). It works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system, increasing their availability at synaptic sites. The mechanism is characteristic of serotonin-norepinephrine reuptake inhibitors (SNRIs).
Product is in LOE-approaching stage with modest Part D spending of $26M annually, indicating a mature franchise with potential team restructuring ahead.
MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects
Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers
Study Evaluating Effexor XR in Chinese Subjects With Major Depressive Disorder
Worked on EFFEXOR XR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on EFFEXOR XR offers limited growth trajectory given its LOE-approaching status and established competitive position, but provides stable, predictable work managing a well-known franchise with consistent patient volumes. Career development is best suited for professionals seeking to execute mature-brand strategies, manage legacy products, or transition to higher-growth pipeline assets.